You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

PREDNISONE - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for prednisone and what is the scope of freedom to operate?

Prednisone is the generic ingredient in thirteen branded drugs marketed by Hikma, Xttrium Labs Inc, Muro, Actavis Labs Fl Inc, Horizon, Halsey, Bayer Pharms, Pharmacia And Upjohn, Ferndale Labs, Schering, Solvay, Parke Davis, Schwarz Pharma, Allied, Am Therap, Amneal, Amneal Pharms Ny, Aurobindo Pharma Ltd, Bundy, Chartwell Molecular, Chartwell Rx, Contract Pharmacal, Duramed Pharms Barr, Elkins Sinn, Endo Operations, Everylife, Ferrante, Geneyork Pharms, Heather, Hikma Pharms, Impax Labs, Inwood Labs, Ivax Sub Teva Pharms, Jubilant Cadista, Kv Pharm, Lederle, Marshall Pharma, Mutual Pharm, Mylan, Novitium Pharma, Nylos, Panray, Pharmavite, Phoenix Labs Ny, Purepac Pharm, Pvt Form, Rexall, Rising, Roxane, Sandoz, Scherer Labs, Sperti, Strides Pharma, Sun Pharm Industries, Superpharm, Teva, UDL, Upsher Smith, Valeant Pharm Intl, Vangard, Vitarine, Watson Labs, and Whiteworth Town Plsn, and is included in one hundred and twenty-eight NDAs. There are six patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Prednisone has fifty-three patent family members in twenty-nine countries.

There are sixteen drug master file entries for prednisone. Fifty-one suppliers are listed for this compound.

Drug Prices for PREDNISONE

See drug prices for PREDNISONE

Drug Sales Revenue Trends for PREDNISONE

See drug sales revenues for PREDNISONE

Recent Clinical Trials for PREDNISONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Zhejiang UniversityPhase 3
Merck Sharp & Dohme LLCPhase 3
Orion Corporation, Orion PharmaPhase 3

See all PREDNISONE clinical trials

Pharmacology for PREDNISONE
Medical Subject Heading (MeSH) Categories for PREDNISONE
Paragraph IV (Patent) Challenges for PREDNISONE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RAYOS Delayed-release Tablets prednisone 5 mg 202020 1 2012-11-26

US Patents and Regulatory Information for PREDNISONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Inwood Labs PREDNISONE prednisone TABLET;ORAL 080279-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Vitarine PREDNISONE prednisone TABLET;ORAL 080334-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan PREDNISONE prednisone TABLET;ORAL 083677-001 Approved Prior to Jan 1, 1982 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs PREDNISONE prednisone TABLET;ORAL 085162-001 Approved Prior to Jan 1, 1982 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mutual Pharm PREDNISONE prednisone TABLET;ORAL 086595-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PREDNISONE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-002 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
Horizon RAYOS prednisone TABLET, DELAYED RELEASE;ORAL 202020-001 Jul 26, 2012 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PREDNISONE

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2008015018 ⤷  Sign Up
China 101466385 Delayed-release glucocorticoid treatment of rheumatoid disease ⤷  Sign Up
Spain 2400446 ⤷  Sign Up
Russian Federation 2005132451 ТАБЛЕТКА ОСОБОЙ ГЕОРМЕТРИЧЕСКОЙ ФОРМЫ С МЕДЛЕННЫМВЫСВОБОЖДЕНИЕМ АКТИВНОГО ВЕЩЕСТВА ⤷  Sign Up
European Patent Office 1631251 COMPRIME A ACTION RETARDEE ET A GEOMETRIE DE NOYAU DEFINIE (DELAYED RELEASE TABLET WITH DEFINED CORE GEOMETRY) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.